Thus, the combination of the CCR7 function-blocking antibody along with a p-AKT antagonist may serve as a platform for a therapeutic against KRAS-expressing metastatic colorectal cancer [123]. This evidence concerns the gene KRAS and metastatic colorectal cancer.